Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983400 | 0.89 | LTA4H (0.40) | CHRNA3CHRNB2CHRNA4PIK3CDLTA4H | |
| SCHEMBL31268854 | 0.87 | CHRNA3 (0.35) | CHRNA3CHRNB2CHRNA4PRKCZPIK3CD | |
| SCHEMBL31269268 | 0.86 | CHRNB4 (0.40) | CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL31268923 | 0.85 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL31269162 | 0.85 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL31269013 | 0.84 | PIK3CD (0.39) | PRKCZPIK3CD | |
| SCHEMBL31269171 | 0.84 | DRD2 (0.37) | PIK3CD | |
| SCHEMBL31268820 | 0.83 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL31269018 | 0.83 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL30983386 | 0.83 | PIK3CD (0.38) | CHRNA3CHRNB2CHRNA4PIK3CDLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |